Management of stage I non-small cell lung cancer:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
2007
|
| Schriftenreihe: | Thoracic surgery clinics
17,2 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIV S., S. 138 - 307 Ill., graph. Darst. |
| ISBN: | 9781416051411 1416051414 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV022536247 | ||
| 003 | DE-604 | ||
| 005 | 20070806 | ||
| 007 | t | ||
| 008 | 070731s2007 ad|| |||| 00||| eng d | ||
| 020 | |a 9781416051411 |9 978-1-4160-5141-1 | ||
| 020 | |a 1416051414 |9 1-4160-5141-4 | ||
| 035 | |a (OCoLC)488242300 | ||
| 035 | |a (DE-599)BVBBV022536247 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 084 | |a XH 5765 |0 (DE-625)152918:13144 |2 rvk | ||
| 084 | |a YI 7600 |0 (DE-625)153688:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Management of stage I non-small cell lung cancer |c guest ed. Rodney J. Landreneau |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2007 | |
| 300 | |a XIV S., S. 138 - 307 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Thoracic surgery clinics |v 17,2 | |
| 650 | 0 | 7 | |a Nicht-kleinzelliges Bronchialkarzinom |0 (DE-588)4633228-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Nicht-kleinzelliges Bronchialkarzinom |0 (DE-588)4633228-5 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Landreneau, Rodney |e Sonstige |4 oth | |
| 830 | 0 | |a Thoracic surgery clinics |v 17,2 |w (DE-604)BV019335438 |9 17,2 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015742757&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015742757 | ||
Datensatz im Suchindex
| _version_ | 1804136647722270720 |
|---|---|
| adam_text | CONTENTS
Preface xiii
Rodney J. Landreneau
The Role of CT Screening for Lung Cancer 137
Claudia I. Henschke, David F. Yankelevitz, and Nasser K. Altorki
A person at high risk for lung cancer and who is asymptomatic and interested in poten¬
tially being screened should be fully apprized of the implications of screening and of the
treatment that may result. It is reasonable for the individual to choose to be screened by a
multidisciplinary medical team with experience in performing such screenings, using a
well defined CT regimen of screening, and having appropriate quality assurance proce¬
dures in place.
CT Directed Diagnosis of Peripheral Lung Lesions Suspicious for Cancer 143
David F. Yankelevitz, Matthew D. Cham, Ali O. Farooqi,
and Claudia I. Henschke
Small peripheral pulmonary nodules continue to be a diagnostic challenge, and because
of improved technology are also being identified with increased frequency. Transthoracic
needle biopsy, performed properly, is a highly accurate procedure and with careful
attention to technical factors, nodules of any size in any location may undergo biopsy.
A skilled cytologist is an essential part of the team. Continued advances in molecular
diagnostics will allow for an expanded role of the usefulness of this procedure.
Bronchoscopic Directed Diagnosis of Peripheral Lung Lesions Suspicious
for Cancer 159
Inderjit K. Hansra and Armin Ernst
Peripheral lung lesions are often difficult to sample by conventional bronchoscopy alone.
New advances in endobronchial ultrasound and electromagnetic navigation have
allowed bronchoscopists to reach lesions not reliably attainable before the introduction
of these technologies. Many peripheral intrapulmonary lesions that may have previously
been referred for surgical biopsy procedures or a CT guided diagnostic intervention can
now be approached minimally invasively.
VOLUME 17 • NUMBER 2 • MAY 2007 vii
Prognostic Modeling in Early Stage Lung Cancer: An Evolving Process
from Histopathology to Genomics 167
David H. Harpole, Jr
The goal is to validate a molecular based tumor model that identifies patients at low risk
for cancer recurrence and who will not benefit from adjuvant chemotherapy. The remain¬
ing patients will be randomized to observation (present standard of care) or adjuvant
chemotherapy to determine efficacy of adjuvant in this population. Investigators have
focused on the identification of markers that may predict poor prognosis as a way to
enrich the population by separating those likely to have early recurrence and cancer
death from those not needing additional treatment after resection. The initial projects
refined predictive models of cancer recurrence after resection for patients with early
stage non small cell lung cancer.
Role of Sublobar Resection (Segmentectomy and Wedge Resection)
in the Surgical Management of Non Small Cell Lung Cancer 175
Brian L. Pettiford, Matthew J. Schuchert, Ricardo Santos,
and Rodney J. Landreneau
The use of sublobar resection as definitive management of resectable non small cell lung
cancer (NSCLC) has been a controversial topic throughout the history of surgery for lung
cancer. Most thoracic surgeons continue to consider pulmonary resection less than lo
bectomy as inadequate for the management of lung cancers anatomically confined to
a single lobe of the lung. The increasingly common finding of new subcentimeter malig¬
nant lesions identified through surveillance CT chest scanning efforts has led many sur¬
geons to reassess the need for total lobectomy for the management of smaller peripheral
NSCLCs. This article reviews the clinical information available today in formulating an
opinion regarding the appropriate use of sublobar resection for the small peripherally
located NSCLC. The technical details of the most commonly performed segmental resec¬
tions are also described.
Management of the Peripheral Small Ground Glass Opacities 191
Junji Yoshida
Pure ground glass opacities (GGO) with a small consolidation area are mostly bronchio
loalveolar carcinomas that have not yet become invasive, whereas a minority represents
only inflammatory changes. Even if they are cancers, they are slow growing and often
remain unchanged for several years. There is no need for immediate resection of GGO
lesions and a watchful waiting strategy is recommended. It seems that a lower impact
surgery (eg, wedge resection or segmentectomy) is curative for these lung cancers.
Because high resolution CT seems to predict noninvasive or minimally invasive GGO
lung cancers with high reliability, less invasive treatments like radiofrequency ablation
have greater appeal.
Open Lobectomy for Patients with Stage I Non Small Cell Lung Cancer 203
Shawn S. Groth and Michael A. Maddaus
Because the tumor is contained within a foci of lung parenchyma, the foundation of
treatment of stage I non small cell lung cancer is complete resection of the neoplasm
and achieving microscopically negative margins. The choice of operation is crucial.
Because of its more favorable local recurrence and 5 year survival rates, lobectomy with
mediastinal lymphadenectomy is the gold standard for treating patients with clinical
stage I non small cell lung cancer who have sufficient cardiopulmonary reserve, includ¬
ing older patients.
viii CONTENTS
Role of Lymphadenectomy in the Treatment of Clinical Stage I Non Small
Cell Lung Cancer 217
Tiziano De Giacomo, Federico Venuta, and Erino Angelo Rendina
It has been proved with acceptable certainty that mediastinal lymph node dissection
does not increase complications in lung cancer surgery and improves the accuracy of sta¬
ging. This applies to lung cancer at all resectable stages. As far as survival is concerned,
statistically significant differences have been suggested by some authors and are more
evident for early stages. Stage I non small cell lung cancer, a local disease, may profit
from lymph node dissection, a procedure that can effectively control local tumor, reduce
local recurrence, and improve long term survival.
Video Assisted Thoracoscopic Surgery Lobectomy for Stage I Lung Cancer 223
Ali Mahtabifard, Daniel T. DeArmond, Clark B. Fuller,
and Robert J. McKenna, Jr
Video assisted thoracoscopic surgery (VATS) is an appealing alternative to thoracotomy
for lobectomy in patients who have stage I lung cancer. The success of laparoscopy in the
1980s and improved endoscopic video systems and endoscopic staplers led thoracic
surgeons to apply this technology to the chest cavity. Since the first VATS lobectomy with
anatomic hilar dissection performed in 1992, investigators from around the world have
published small series that report the safety and advantages of this approach. This article
reviews the current literature of VATS lobectomy for stage I lung cancer.
Variation in the Approach to VATS Lobectomy: Effect on the Evaluation
of Surgical Morbidity Following VATS Lobectomy for the Treatment
of Stage I Non Small Cell Lung Cancer 233
Norihisa Shigemura and Anthony P.C. Yim
Recent advances in imaging, chemical pathology, and target therapy have made it neces¬
sary to redefine the role of surgery in the therapeutic algorithm in the management of
lung cancer. Although video assisted thoracic surgery lobectomy with hilar and mediast¬
inal lymph node dissection was proposed over a decade ago to treat early lung cancer,
this technique is currently not widely practiced, despite many documented advantages.
This article examines the role of video assisted thoracic surgery lobectomy in the treat¬
ment of early lung cancer and, in particular, variations in the approach and published
results.
Immunologic and Stress Responses Following Video Assisted Thoracic
Surgery and Open Pulmonary Lobectomy in Early Stage Lung Cancer 241
William S. Walker and H. Anne Leaver
Conventional open major surgery evokes an injury response involving endocrine, neur¬
al, and immunologic mechanisms. The immunologic responses are characterized by
release of cytokines, inflammatory mediators, and acute phase proteins and by adverse
disturbances in immune cell function. The use of a minimal access approach strategy is
associated with a significant reduction in the cytokine response, as exemplified by
reduced interleukin 6 levels and a corresponding reduction in acute phase protein
generation with reduced C reactive protein levels. Circulating immune cell function
and numbers also are better preserved. These changes have been demonstrated in com¬
paring open with video assisted thoracoscopic surgery (VATS) lobectomy and, together
with further investigation into local immune function, may offer some insight into the
excellent survival data reported for VATS resection of stage I non small cell lung cancer.
CONTENTS i*
Stereotactic Body Radiation Therapy for Stage I Non Small Cell Lung
Cancer 251
Joe Y. Chang and Jack A. Roth
Conventional fractionated radiotherapy has resulted in 5 year local control rates of 30%
to 50% and overall survival rates of 10% to 30% in stage I inoperable non small cell lung
cancer (NSCLC). Early stage NSCLC is not inherently a systemic disease at the time of
diagnosis; research directed toward improving survival should put more emphasis on
improving local tumor obliteration. Image guided hypofractionated stereotactic body ra¬
diation therapy can deliver a high biologic effective dose to the target while minimizing
the normal tissue toxicities, which may translate into improved local control and sur¬
vival rates. This article discusses the rationale, indications, and optimal techniques for
stereotactic body radiation therapy and comparison with surgical resection in patients
with stage I NSCLC.
Ablative Treatments for Lung Tumors: Radiofrequency Ablation, Stereotactic
Radiosurgery, and Microwave Ablation 261
Ghulam Abbas, Matthew J. Schuchert, Arjun Pennathur, Sebastien Gilbert,
and James D. Luketich
New alternatives to standard external beam radiation therapy are now entering clinical
practice for the treatment of lung cancer or limited pulmonary metastases in medically
inoperable patients. The two principal modalities that are being offered by many centers
around the world are radiofrequency ablation and stereotactic radiosurgery. Another
ablative modality, microwave ablation, is also being introduced into practice, although
current clinical experience is very limited with this new approach. This article reviews
these therapies and discusses their role in the treatment of thoracic malignancies.
Role of Adjuvant Radiation (External Beam/Brachytherapy)
for Stage I NSCLC 273
Ara Ketchedjian, Thomas A. DiPetrillo, Benedict Daly, and Hiran C. Fernando
The role of adjuvant radiation following surgical treatment of non small cell lung cancer
(NSCLC) is reviewed in this article. There seems to be no role for adjuvant radiation in
stage I NSCLC patients treated by lobectomy. Adjuvant brachytherapy in combination
with sublobar resection is a promising approach that seems to decrease local recurrence
rates similar to that reported following lobectomy. Radiofrequency ablation is an alter¬
native for the high risk patient with NSCLC who is considered too high risk even for
sublobar resection. In particular, adjuvant stereotactic radiation should be investigated
as a potential method of decreasing local recurrence and preserving lung function in
these high risk patients.
Role of Adjuvant Systemic Therapy for Stage I NSCLC 279
Eric Vallieres
Results of trials reported in the last four years have convincingly demonstrated a role for
adjuvant or postoperative chemotherapy in the management of good performance status
patients after a complete resection of their stages II and IIIA non small cell lung cancer.
The role of chemotherapy after surgery of stage I disease, however, remains a subject of
debate. This article reviews the limited data that pertain to this approach in early stage
disease and set the stage for future trials in this population of patients.
* CONTENTS
Adjuvant Chemotherapy and the Role of Chemotherapy Resistance Testing
for Stage I Non Small Cell Lung Cancer 287
Thomas A. d Amato
This article describes the current clinical application of in vitro chemotherapy resistance
testing of patient tumors. The frequency of in vitro chemotherapy resistance in non
small cell lung cancer is extraordinary; however, its clinical relevance remains unproved.
Future studies on the use of the extreme drug resistant assay and its integration into clin¬
ical trials is justified. The staggering prevalence of non small cell lung cancer in vitro
tumor resistance is reviewed, and the potential role of the extreme drug resistant assay
in both clinical and laboratory investigations are discussed.
Index 301
CONTENTS xi
|
| adam_txt |
CONTENTS
Preface xiii
Rodney J. Landreneau
The Role of CT Screening for Lung Cancer 137
Claudia I. Henschke, David F. Yankelevitz, and Nasser K. Altorki
A person at high risk for lung cancer and who is asymptomatic and interested in poten¬
tially being screened should be fully apprized of the implications of screening and of the
treatment that may result. It is reasonable for the individual to choose to be screened by a
multidisciplinary medical team with experience in performing such screenings, using a
well defined CT regimen of screening, and having appropriate quality assurance proce¬
dures in place.
CT Directed Diagnosis of Peripheral Lung Lesions Suspicious for Cancer 143
David F. Yankelevitz, Matthew D. Cham, Ali O. Farooqi,
and Claudia I. Henschke
Small peripheral pulmonary nodules continue to be a diagnostic challenge, and because
of improved technology are also being identified with increased frequency. Transthoracic
needle biopsy, performed properly, is a highly accurate procedure and with careful
attention to technical factors, nodules of any size in any location may undergo biopsy.
A skilled cytologist is an essential part of the team. Continued advances in molecular
diagnostics will allow for an expanded role of the usefulness of this procedure.
Bronchoscopic Directed Diagnosis of Peripheral Lung Lesions Suspicious
for Cancer 159
Inderjit K. Hansra and Armin Ernst
Peripheral lung lesions are often difficult to sample by conventional bronchoscopy alone.
New advances in endobronchial ultrasound and electromagnetic navigation have
allowed bronchoscopists to reach lesions not reliably attainable before the introduction
of these technologies. Many peripheral intrapulmonary lesions that may have previously
been referred for surgical biopsy procedures or a CT guided diagnostic intervention can
now be approached minimally invasively.
VOLUME 17 • NUMBER 2 • MAY 2007 vii
Prognostic Modeling in Early Stage Lung Cancer: An Evolving Process
from Histopathology to Genomics 167
David H. Harpole, Jr
The goal is to validate a molecular based tumor model that identifies patients at low risk
for cancer recurrence and who will not benefit from adjuvant chemotherapy. The remain¬
ing patients will be randomized to observation (present standard of care) or adjuvant
chemotherapy to determine efficacy of adjuvant in this population. Investigators have
focused on the identification of markers that may predict poor prognosis as a way to
"enrich" the population by separating those likely to have early recurrence and cancer
death from those not needing additional treatment after resection. The initial projects
refined predictive models of cancer recurrence after resection for patients with early
stage non small cell lung cancer.
Role of Sublobar Resection (Segmentectomy and Wedge Resection)
in the Surgical Management of Non Small Cell Lung Cancer 175
Brian L. Pettiford, Matthew J. Schuchert, Ricardo Santos,
and Rodney J. Landreneau
The use of sublobar resection as definitive management of resectable non small cell lung
cancer (NSCLC) has been a controversial topic throughout the history of surgery for lung
cancer. Most thoracic surgeons continue to consider pulmonary resection less than lo
bectomy as inadequate for the management of lung cancers anatomically confined to
a single lobe of the lung. The increasingly common finding of new subcentimeter malig¬
nant lesions identified through surveillance CT chest scanning efforts has led many sur¬
geons to reassess the need for total lobectomy for the management of smaller peripheral
NSCLCs. This article reviews the clinical information available today in formulating an
opinion regarding the appropriate use of sublobar resection for the small peripherally
located NSCLC. The technical details of the most commonly performed segmental resec¬
tions are also described.
Management of the Peripheral Small Ground Glass Opacities 191
Junji Yoshida
Pure ground glass opacities (GGO) with a small consolidation area are mostly bronchio
loalveolar carcinomas that have not yet become invasive, whereas a minority represents
only inflammatory changes. Even if they are cancers, they are slow growing and often
remain unchanged for several years. There is no need for immediate resection of GGO
lesions and a watchful waiting strategy is recommended. It seems that a lower impact
surgery (eg, wedge resection or segmentectomy) is curative for these lung cancers.
Because high resolution CT seems to predict noninvasive or minimally invasive GGO
lung cancers with high reliability, less invasive treatments like radiofrequency ablation
have greater appeal.
Open Lobectomy for Patients with Stage I Non Small Cell Lung Cancer 203
Shawn S. Groth and Michael A. Maddaus
Because the tumor is contained within a foci of lung parenchyma, the foundation of
treatment of stage I non small cell lung cancer is complete resection of the neoplasm
and achieving microscopically negative margins. The choice of operation is crucial.
Because of its more favorable local recurrence and 5 year survival rates, lobectomy with
mediastinal lymphadenectomy is the gold standard for treating patients with clinical
stage I non small cell lung cancer who have sufficient cardiopulmonary reserve, includ¬
ing older patients.
viii CONTENTS
Role of Lymphadenectomy in the Treatment of Clinical Stage I Non Small
Cell Lung Cancer 217
Tiziano De Giacomo, Federico Venuta, and Erino Angelo Rendina
It has been proved with acceptable certainty that mediastinal lymph node dissection
does not increase complications in lung cancer surgery and improves the accuracy of sta¬
ging. This applies to lung cancer at all resectable stages. As far as survival is concerned,
statistically significant differences have been suggested by some authors and are more
evident for early stages. Stage I non small cell lung cancer, a local disease, may profit
from lymph node dissection, a procedure that can effectively control local tumor, reduce
local recurrence, and improve long term survival.
Video Assisted Thoracoscopic Surgery Lobectomy for Stage I Lung Cancer 223
Ali Mahtabifard, Daniel T. DeArmond, Clark B. Fuller,
and Robert J. McKenna, Jr
Video assisted thoracoscopic surgery (VATS) is an appealing alternative to thoracotomy
for lobectomy in patients who have stage I lung cancer. The success of laparoscopy in the
1980s and improved endoscopic video systems and endoscopic staplers led thoracic
surgeons to apply this technology to the chest cavity. Since the first VATS lobectomy with
anatomic hilar dissection performed in 1992, investigators from around the world have
published small series that report the safety and advantages of this approach. This article
reviews the current literature of VATS lobectomy for stage I lung cancer.
Variation in the Approach to VATS Lobectomy: Effect on the Evaluation
of Surgical Morbidity Following VATS Lobectomy for the Treatment
of Stage I Non Small Cell Lung Cancer 233
Norihisa Shigemura and Anthony P.C. Yim
Recent advances in imaging, chemical pathology, and target therapy have made it neces¬
sary to redefine the role of surgery in the therapeutic algorithm in the management of
lung cancer. Although video assisted thoracic surgery lobectomy with hilar and mediast¬
inal lymph node dissection was proposed over a decade ago to treat early lung cancer,
this technique is currently not widely practiced, despite many documented advantages.
This article examines the role of video assisted thoracic surgery lobectomy in the treat¬
ment of early lung cancer and, in particular, variations in the approach and published
results.
Immunologic and Stress Responses Following Video Assisted Thoracic
Surgery and Open Pulmonary Lobectomy in Early Stage Lung Cancer 241
William S. Walker and H. Anne Leaver
Conventional open major surgery evokes an injury response involving endocrine, neur¬
al, and immunologic mechanisms. The immunologic responses are characterized by
release of cytokines, inflammatory mediators, and acute phase proteins and by adverse
disturbances in immune cell function. The use of a minimal access approach strategy is
associated with a significant reduction in the cytokine response, as exemplified by
reduced interleukin 6 levels and a corresponding reduction in acute phase protein
generation with reduced C reactive protein levels. Circulating immune cell function
and numbers also are better preserved. These changes have been demonstrated in com¬
paring open with video assisted thoracoscopic surgery (VATS) lobectomy and, together
with further investigation into local immune function, may offer some insight into the
excellent survival data reported for VATS resection of stage I non small cell lung cancer.
CONTENTS i*
Stereotactic Body Radiation Therapy for Stage I Non Small Cell Lung
Cancer 251
Joe Y. Chang and Jack A. Roth
Conventional fractionated radiotherapy has resulted in 5 year local control rates of 30%
to 50% and overall survival rates of 10% to 30% in stage I inoperable non small cell lung
cancer (NSCLC). Early stage NSCLC is not inherently a systemic disease at the time of
diagnosis; research directed toward improving survival should put more emphasis on
improving local tumor obliteration. Image guided hypofractionated stereotactic body ra¬
diation therapy can deliver a high biologic effective dose to the target while minimizing
the normal tissue toxicities, which may translate into improved local control and sur¬
vival rates. This article discusses the rationale, indications, and optimal techniques for
stereotactic body radiation therapy and comparison with surgical resection in patients
with stage I NSCLC.
Ablative Treatments for Lung Tumors: Radiofrequency Ablation, Stereotactic
Radiosurgery, and Microwave Ablation 261
Ghulam Abbas, Matthew J. Schuchert, Arjun Pennathur, Sebastien Gilbert,
and James D. Luketich
New alternatives to standard external beam radiation therapy are now entering clinical
practice for the treatment of lung cancer or limited pulmonary metastases in medically
inoperable patients. The two principal modalities that are being offered by many centers
around the world are radiofrequency ablation and stereotactic radiosurgery. Another
ablative modality, microwave ablation, is also being introduced into practice, although
current clinical experience is very limited with this new approach. This article reviews
these therapies and discusses their role in the treatment of thoracic malignancies.
Role of Adjuvant Radiation (External Beam/Brachytherapy)
for Stage I NSCLC 273
Ara Ketchedjian, Thomas A. DiPetrillo, Benedict Daly, and Hiran C. Fernando
The role of adjuvant radiation following surgical treatment of non small cell lung cancer
(NSCLC) is reviewed in this article. There seems to be no role for adjuvant radiation in
stage I NSCLC patients treated by lobectomy. Adjuvant brachytherapy in combination
with sublobar resection is a promising approach that seems to decrease local recurrence
rates similar to that reported following lobectomy. Radiofrequency ablation is an alter¬
native for the high risk patient with NSCLC who is considered too high risk even for
sublobar resection. In particular, adjuvant stereotactic radiation should be investigated
as a potential method of decreasing local recurrence and preserving lung function in
these high risk patients.
Role of Adjuvant Systemic Therapy for Stage I NSCLC 279
Eric Vallieres
Results of trials reported in the last four years have convincingly demonstrated a role for
adjuvant or postoperative chemotherapy in the management of good performance status
patients after a complete resection of their stages II and IIIA non small cell lung cancer.
The role of chemotherapy after surgery of stage I disease, however, remains a subject of
debate. This article reviews the limited data that pertain to this approach in early stage
disease and set the stage for future trials in this population of patients.
* CONTENTS
Adjuvant Chemotherapy and the Role of Chemotherapy Resistance Testing
for Stage I Non Small Cell Lung Cancer 287
Thomas A. d'Amato
This article describes the current clinical application of in vitro chemotherapy resistance
testing of patient tumors. The frequency of in vitro chemotherapy resistance in non
small cell lung cancer is extraordinary; however, its clinical relevance remains unproved.
Future studies on the use of the extreme drug resistant assay and its integration into clin¬
ical trials is justified. The staggering prevalence of non small cell lung cancer in vitro
tumor resistance is reviewed, and the potential role of the extreme drug resistant assay
in both clinical and laboratory investigations are discussed.
Index 301
CONTENTS xi |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV022536247 |
| classification_rvk | XH 5765 YI 7600 |
| ctrlnum | (OCoLC)488242300 (DE-599)BVBBV022536247 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01635nam a2200397 cb4500</leader><controlfield tag="001">BV022536247</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20070806 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">070731s2007 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781416051411</subfield><subfield code="9">978-1-4160-5141-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416051414</subfield><subfield code="9">1-4160-5141-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)488242300</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV022536247</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 5765</subfield><subfield code="0">(DE-625)152918:13144</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YI 7600</subfield><subfield code="0">(DE-625)153688:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Management of stage I non-small cell lung cancer</subfield><subfield code="c">guest ed. Rodney J. Landreneau</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIV S., S. 138 - 307</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Thoracic surgery clinics</subfield><subfield code="v">17,2</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nicht-kleinzelliges Bronchialkarzinom</subfield><subfield code="0">(DE-588)4633228-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Nicht-kleinzelliges Bronchialkarzinom</subfield><subfield code="0">(DE-588)4633228-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Landreneau, Rodney</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Thoracic surgery clinics</subfield><subfield code="v">17,2</subfield><subfield code="w">(DE-604)BV019335438</subfield><subfield code="9">17,2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015742757&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015742757</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV022536247 |
| illustrated | Illustrated |
| index_date | 2024-07-02T18:08:28Z |
| indexdate | 2024-07-09T20:59:44Z |
| institution | BVB |
| isbn | 9781416051411 1416051414 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015742757 |
| oclc_num | 488242300 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XIV S., S. 138 - 307 Ill., graph. Darst. |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Saunders |
| record_format | marc |
| series | Thoracic surgery clinics |
| series2 | Thoracic surgery clinics |
| spelling | Management of stage I non-small cell lung cancer guest ed. Rodney J. Landreneau Philadelphia [u.a.] Saunders 2007 XIV S., S. 138 - 307 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Thoracic surgery clinics 17,2 Nicht-kleinzelliges Bronchialkarzinom (DE-588)4633228-5 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Nicht-kleinzelliges Bronchialkarzinom (DE-588)4633228-5 s Therapie (DE-588)4059798-2 s b DE-604 Landreneau, Rodney Sonstige oth Thoracic surgery clinics 17,2 (DE-604)BV019335438 17,2 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015742757&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Management of stage I non-small cell lung cancer Thoracic surgery clinics Nicht-kleinzelliges Bronchialkarzinom (DE-588)4633228-5 gnd Therapie (DE-588)4059798-2 gnd |
| subject_GND | (DE-588)4633228-5 (DE-588)4059798-2 (DE-588)4143413-4 |
| title | Management of stage I non-small cell lung cancer |
| title_auth | Management of stage I non-small cell lung cancer |
| title_exact_search | Management of stage I non-small cell lung cancer |
| title_exact_search_txtP | Management of stage I non-small cell lung cancer |
| title_full | Management of stage I non-small cell lung cancer guest ed. Rodney J. Landreneau |
| title_fullStr | Management of stage I non-small cell lung cancer guest ed. Rodney J. Landreneau |
| title_full_unstemmed | Management of stage I non-small cell lung cancer guest ed. Rodney J. Landreneau |
| title_short | Management of stage I non-small cell lung cancer |
| title_sort | management of stage i non small cell lung cancer |
| topic | Nicht-kleinzelliges Bronchialkarzinom (DE-588)4633228-5 gnd Therapie (DE-588)4059798-2 gnd |
| topic_facet | Nicht-kleinzelliges Bronchialkarzinom Therapie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015742757&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV019335438 |
| work_keys_str_mv | AT landreneaurodney managementofstageinonsmallcelllungcancer |